Insurance coverage for Zepbound (tirzepatide) depends on individual insurance plans and their formulary. Many insurance plans do not cover weight-loss medications, but coverage is expanding.
Will my insurance plan cover Zepbound?
The availability of Zepbound coverage varies by insurance provider and specific plan. Factors influencing coverage include whether the medication is on the plan's formulary, if prior authorization is required, and if there are any step-therapy requirements. Some plans may offer coverage for Zepbound when used for type 2 diabetes (under its brand name Mounjaro) but not for weight management. Patients are advised to check directly with their insurance provider for details specific to their plan.
What if my insurance doesn't cover Zepbound?
If Zepbound is not covered by your insurance, alternative options may be available. Eli Lilly, the manufacturer of Zepbound, offers a savings card that can reduce out-of-pocket costs for eligible commercially insured patients. This card can provide savings of up to $150 per month, with a potential out-of-pocket cost as low as $550 per prescription for those with commercial insurance.
How does Zepbound compare to other weight-loss medications?
Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, approved for chronic weight management in adults with obesity or overweight who have at least one weight-related condition. It works by reducing appetite and increasing feelings of fullness. Other medications in the GLP-1 receptor agonist class, such as semaglutide (Wegovy), also target weight loss. Clinical trials have shown significant weight reduction with Zepbound compared to placebo.
When was Zepbound approved for use?
The U.S. Food and Drug Administration (FDA) approved Zepbound for chronic weight management on November 8, 2023 [1].
What are the potential side effects of Zepbound?
Common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, abdominal pain, and decreased appetite. More serious but less common side effects can include pancreatitis, gallbladder problems, kidney problems, and severe allergic reactions. Zepbound carries a boxed warning for the risk of thyroid C-cell tumors, which has been observed in animal studies. It should not be used by individuals with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 [2].
What clinical data supports Zepbound's effectiveness?
The FDA approval of Zepbound was based on two large studies, the SURMOUNT-1 and SURMOUNT-2 trials. In the SURMOUNT-1 trial, participants taking Zepbound achieved an average weight loss of 22.5% over 72 weeks. In the SURMOUNT-2 trial, which included participants with type 2 diabetes, Zepbound resulted in an average weight loss of 10.9% over 72 weeks [1].
What is the cost of Zepbound?
The list price for Zepbound is $1,059.87 for a 28-day supply. However, out-of-pocket costs can be significantly lower for eligible patients with commercial insurance utilizing the manufacturer's savings card [3].
Are there any patent protections for Zepbound?
Zepbound, which is tirzepatide, is protected by patents. For information on the patent status and expiration dates of tirzepatide and related drugs, resources like DrugPatentWatch.com can provide detailed insights [4].
Sources:
1. https://www.fda.gov/drugs/news-events-human-drugs-news/fda-approves-new-drug-chronic-weight-management
2. https://www.drugpatentwatch.com/p/drugs/tirzepatide/zepbound
3. https://www.fiercepharma.com/marketing/lilly-launches-zepbound-weight-loss-drug-under-150-monthly-list-price-1060
4. https://www.drugpatentwatch.com/